

CELL THERAPEUTICS INC
Form 4
March 21, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Plunkett Matthew

2. Issuer Name and Ticker or Trading Symbol
CELL THERAPEUTICS INC
[CTIC]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
3101 WESTERN AVENUE, SUITE 600

3. Date of Earliest Transaction (Month/Day/Year)
03/21/2014

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
EVP, Corporate Development

(Street)
SEATTLE, WA 98121

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/21/2014		S		8,000	D	\$ 3.71 782,904
Common Stock	03/21/2014		S		600	D	\$ 3.712 782,304
Common Stock	03/21/2014		S		10,158	D	\$ 3.715 772,146
Common Stock	03/21/2014		S		68,656	D	\$ 3.72 703,490
Common Stock	03/21/2014		S		2,500	D	\$ 3.721 700,990

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Common Stock	03/21/2014	S	300	D	\$ 3.722	700,690	D
Common Stock	03/21/2014	S	22,086	D	\$ 3.725	678,604	D
Common Stock	03/21/2014	S	18,600	D	\$ 3.73	660,004	D
Common Stock	03/21/2014	S	400	D	\$ 3.731	659,604	D
Common Stock	03/21/2014	S	1,400	D	\$ 3.732	658,204	D
Common Stock	03/21/2014	S	10,800	D	\$ 3.735	647,404	D
Common Stock	03/21/2014	S	100	D	\$ 3.739	647,304	D
Common Stock	03/21/2014	S	9,000	D	\$ 3.74	638,304	D
Common Stock	03/21/2014	S	400	D	\$ 3.742	637,904	D
Common Stock	03/21/2014	S	14,000	D	\$ 3.745	623,904	D
Common Stock	03/21/2014	S	100	D	\$ 3.747	623,804	D
Common Stock	03/21/2014	S	300	D	\$ 3.748	623,504	D
Common Stock	03/21/2014	S	200	D	\$ 3.749	623,304	D
Common Stock	03/21/2014	S	300	D	\$ 3.75	623,004	D
Common Stock	03/21/2014	S	1,100	D	\$ 3.752	621,904	D
Common Stock	03/21/2014	S	1,000	D	\$ 3.755	620,904	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: CELL THERAPEUTICS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121			EVP, Corporate Development	

Signatures

Louis A. Bianco, Attorney-in-fact for Matthew Plunkett
 **Signature of Reporting Person
 Date: 03/21/2014

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.